CGTX — Cognition Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$1.01
-$0.02 (-1.94%)
Cognition Therapeutics Inc (CGTX) is a biotechnology company listed on NASDAQ. It is led by Lisa Ricciardi, based in 2500 Westchester Ave., Purchase, NY, United States, 10577, with about 14 employees. Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Net income was -$4.9M. CGTX currently screens at market cap $120.8M.
Use this CGTX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CGTX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CGTX SEC filings page. Lician reads the product cache first so this HTML stays unique to Cognition Therapeutics Inc even when a live quote feed is slow.
About Cognition Therapeutics Inc
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
CGTX Key Statistics
Market Cap
$120.82M
Volume
463,145
Previous Close
$1.03
Day Range
$0.99 – $1.06
EPS
-$0.86
Revenue
$0.00
Net Income
-$33.97M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
14
CGTX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$33.97M | -$25.79M | -$21.40M |
| EPS (Diluted) | -$0.86 | -$0.86 | -$0.91 |
Total Assets
$30.23M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$25.01M
Operating Cash Flow
-$28.47M
Free Cash Flow
$0.00
Cognition Therapeutics Inc Company Information
- CEO, President & Director
- Lisa Ricciardi
- Headquarters
- 2500 Westchester Ave., Purchase, NY, United States, 10577
- Website
- www.cogrx.com
- Phone
- 412 481 2210
- IPO / Founded
- 2021-10-08
- Sector
- Healthcare
- Industry
- Biotechnology